We are live on
!
Find out more
CCM
Camber Capital Management Portfolio holdings
AUM
$1.07B
1-Year Est. Return
8.19%
This Fund
S&P 500
This Quarter
Est. Return
+13.63%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.92B
AUM Growth
-$350M
(-11%)
Cap. Flow
-$342M
Cap. Flow
% of AUM
-11.73%
Top 10 Holdings %
Top 10 Hldgs %
63.81%
Holding
52
New
7
Increased
11
Reduced
10
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
WBA
Walgreens Boots Alliance
WBA
|
+$81.8M |
| 2 |
Tenet Healthcare
THC
|
+$46.2M |
| 3 |
GSK
GSK
|
+$41.6M |
| 4 |
Myriad Genetics
MYGN
|
+$37.3M |
| 5 |
Align Technology
ALGN
|
+$35M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$105M |
| 2 |
Charles River Laboratories
CRL
|
+$98.4M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$67.8M |
| 4 |
Universal Health Services
UHS
|
+$64.9M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$63.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.17% |
| 2 | Miscellaneous | 2.29% |
| 3 | Consumer Discretionary | 0.54% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sanofi
SNY
$102B
| $339M | 11.63% |
7,000,000
-500,000
| -7% | -$21.9M |
|
|
2
Universal Health Services
UHS
$10.4B
| $240M | 8.21% |
1,700,000
-550,000
| -24% | -$64.9M |
|
|
3
Viatris
VTRS
$19.1B
| $223M | 7.63% |
20,000,000
-10,000,000
| -33% | -$105M |
|
|
4
Tenet Healthcare
THC
$21B
| $195M | 6.69% |
4,000,000
+1,000,000
| +33% | +$46.2M |
|
|
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
| $187M | 6.41% |
5,000,000
+2,175,000
| +77% | +$81.8M |
|
6
Sarepta Therapeutics
SRPT
$2.19B
| $162M | 5.56% |
1,250,000
-250,000
| -17% | -$29M |
|
7
Zimmer Biomet
ZBH
$18.8B
| $159M | 5.47% |
1,250,000
-150,000
| -11% | -$17.4M |
|
|
8
GSK
GSK
$100B
| $132M | 4.52% |
3,750,000
+1,250,000
| +50% | +$41.6M |
|
|
SEM
9
DELISTED
Select Medical
SEM
| $119M | 4.09% |
8,908,800
| – | – |
|
10
PTC Therapeutics
PTCT
$5.48B
| $105M | 3.6% |
2,750,000
+300,000
| +12% | +$12.5M |
|
|
11
Myriad Genetics
MYGN
$371M
| $102M | 3.48% |
7,000,000
+2,000,000
| +40% | +$37.3M |
|
12
Perrigo
PRGO
$1.88B
| $85.2M | 2.92% |
2,500,000
| – | – |
|
|
13
Align Technology
ALGN
$10.4B
| $79.1M | 2.71% |
375,000
+175,000
| +88% | +$35M |
|
14
Ionis Pharmaceuticals
IONS
$7.85B
| $72.7M | 2.49% |
1,925,000
| – | – |
|
|
SGEN
15
DELISTED
Seagen Inc. Common Stock
SGEN
| $64.3M | 2.2% |
500,000
+250,000
| +100% | +$32.3M |
|
16
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
| $63.8M | 2.19% |
7,000,000
-500,000
| -7% | -$4.36M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $63.4M | 2.18% |
1,400,000
-600,000
| -30% | -$38.8M |
|
18
Dentsply Sirona
XRAY
$1.96B
| $56.2M | 1.93% |
1,765,000
+350,000
| +25% | +$10.6M |
|
|
19
CALL
Viatris
VTRS
$19.1B
| $55.6M | 1.91% |
+5,000,000
| New | +$52.3M |
|
20
Brookdale Senior Living
BKD
$2.83B
| $49.1M | 1.69% |
18,000,000
+2,000,000
| +13% | +$7.48M |
|
21
Quanterix
QTRX
$129M
| $47.4M | 1.63% |
3,425,000
+425,000
| +14% | +$4.89M |
|
22
Qiagen
QGEN
$8.77B
| $37.4M | 1.28% |
+707,292
| New | +$34.9M |
|
23
Replimune Group
REPL
$1.23B
| $27.2M | 0.93% |
+1,000,000
| New | +$20.8M |
|
|
SAGE
24
DELISTED
Sage Therapeutics
SAGE
| $26.7M | 0.92% |
+700,000
| New | +$26.7M |
|
25
Collegium Pharmaceutical
COLL
$711M
| $24.4M | 0.84% |
1,050,000
| – | – |
|
Similar funds
PP
SAF
NRD
FC
GIM
SC
BWA
CCP
Camber Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Camber Capital Management held 52 positions worth $2.92B, down 11% from $3.27B the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Camber Capital Management withdrew a net $342M in Q4 2022, closing 13 positions and reducing 10 holdings. Its most notable exit was Charles River Laboratories, an estimated $98.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.
Against the trend, Camber Capital Management opened a new position in Qiagen worth $37.4M.
- Camber Capital Management's largest Q4 2022 buy was Qiagen: 707,292 shares worth $37.4M.
- Camber Capital Management added most to Walgreens Boots Alliance in Q4 2022, an estimated $81.8M increase.
- Camber Capital Management's biggest Q4 2022 reduction was Viatris, cutting an estimated $105M.
- Camber Capital Management fully exited Charles River Laboratories in Q4 2022, selling an estimated $98.4M.
- Camber Capital Management's ten largest holdings make up 64% of its $2.92B portfolio in Q4 2022.
- Camber Capital Management opened 7 new positions and closed 13 in Q4 2022.
- Camber Capital Management's portfolio value fell 11% quarter-over-quarter to $2.92B.
Based on Camber Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.